314 related articles for article (PubMed ID: 32514163)
1. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS
Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma.
Chen X; Zhang Y; Mo S; Ma H; Lu Z; Yu S; Chen J
Arch Pathol Lab Med; 2023 Apr; 147(4):465-473. PubMed ID: 35862858
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
4. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
[TBL] [Abstract][Full Text] [Related]
5. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
6. Expression of B7 family checkpoint proteins in cervical cancer.
Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
[TBL] [Abstract][Full Text] [Related]
7. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.
Zhang W; Acuna-Villaorduna A; Kuan K; Gupta S; Hu S; Ohaegbulam K; Albanese J; Kaumaya M; Levy R; Hwang RR; Zang X; Lin J; Liu Q; Maitra R; Goel S
Clin Colorectal Cancer; 2021 Jun; 20(2):161-169. PubMed ID: 33745842
[TBL] [Abstract][Full Text] [Related]
8. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors.
Xie S; Huang J; Qiao Q; Zang W; Hong S; Tan H; Dong C; Yang Z; Ni L
Cancer Immunol Immunother; 2018 Nov; 67(11):1685-1694. PubMed ID: 30128738
[TBL] [Abstract][Full Text] [Related]
9. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer.
Yang J; Tian Z; Gao H; Xiong F; Cao C; Yu J; Shi W; Zhan Q; Yang C
BMC Cancer; 2022 May; 22(1):584. PubMed ID: 35624419
[TBL] [Abstract][Full Text] [Related]
11. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
[TBL] [Abstract][Full Text] [Related]
12. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
13. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma.
Wang Y; Deng J; Wang L; Zhou T; Yang J; Tian Z; Yang J; Chen H; Tang X; Zhao S; Zhou L; Tong A; Xu J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958683
[TBL] [Abstract][Full Text] [Related]
14. Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors.
Mo S; Zong L; Chen X; Ban X; Li M; Lu Z; Yu S; Chen J
Arch Pathol Lab Med; 2023 Feb; 147(2):193-201. PubMed ID: 35671167
[TBL] [Abstract][Full Text] [Related]
15. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
Kim GE; Kim NI; Park MH; Lee JS
Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma.
Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Zheng W; Castrillon DH; Lucas E
Mod Pathol; 2022 Dec; 35(12):1955-1965. PubMed ID: 35804040
[TBL] [Abstract][Full Text] [Related]
17. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes.
Kim NI; Park MH; Cho N; Lee JS
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):246-256. PubMed ID: 35384874
[TBL] [Abstract][Full Text] [Related]
19. Expression status of PD-L1 and B7-H3 in mesothelioma.
Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
[TBL] [Abstract][Full Text] [Related]
20. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
[Next] [New Search]